Your browser is no longer supported. Please, upgrade your browser.
AXSM Axsome Therapeutics, Inc. daily Stock Chart
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own0.30% Shs Outstand37.06M Perf Week2.56%
Market Cap3.19B Forward P/E- EPS next Y-2.90 Insider Trans1.25% Shs Float28.84M Perf Month5.88%
Income-90.20M PEG- EPS next Q-0.62 Inst Own61.40% Short Float12.29% Perf Quarter47.89%
Sales- P/S- EPS this Y-74.40% Inst Trans0.55% Short Ratio4.73 Perf Half Y-4.81%
Book/sh4.21 P/B19.72 EPS next Y-6.60% ROA-69.70% Target Price- Perf Year222.36%
Cash/sh5.14 P/C16.17 EPS next 5Y- ROE-98.60% 52W Range13.64 - 109.94 Perf YTD-19.66%
Dividend- P/FCF- EPS past 5Y-42.80% ROI- 52W High-24.47% Beta3.14
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low508.80% ATR5.03
Employees45 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)52.18 Volatility5.03% 6.24%
OptionableYes Debt/Eq0.13 EPS Q/Q-172.30% Profit Margin- Rel Volume0.41 Prev Close81.92
ShortableYes LT Debt/Eq0.10 EarningsMay 08 BMO Payout- Avg Volume749.79K Price83.04
Recom1.40 SMA205.10% SMA501.40% SMA20026.74% Volume304,140 Change1.37%
Apr-28-20Reiterated H.C. Wainwright Buy $200 → $210
Apr-14-20Initiated Cowen Outperform $95
Dec-30-19Reiterated H.C. Wainwright Buy $170 → $200
Dec-17-19Reiterated H.C. Wainwright Buy $30 → $170
Dec-16-19Reiterated Guggenheim Buy $65 → $158
Oct-16-19Initiated Guggenheim Buy $48
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Jul-08-20 02:41PM  
Jul-07-20 11:14AM  
Jul-03-20 03:19PM  
Jun-29-20 12:49PM  
Jun-26-20 07:00AM  
Jun-15-20 12:24PM  
Jun-07-20 11:30AM  
Jun-04-20 06:27PM  
May-29-20 01:38PM  
May-26-20 12:57PM  
May-23-20 07:36AM  
May-19-20 06:04AM  
May-11-20 11:56AM  
May-09-20 02:00PM  
May-08-20 07:00AM  
May-03-20 03:39PM  
Apr-30-20 08:00AM  
Apr-28-20 11:16AM  
Apr-27-20 06:00AM  
Apr-07-20 12:37PM  
Apr-06-20 06:00AM  
Apr-01-20 01:23PM  
Mar-31-20 05:05PM  
Mar-30-20 06:00AM  
Mar-29-20 08:53AM  
Mar-28-20 09:23PM  
Mar-23-20 12:17PM  
Mar-20-20 07:00AM  
Mar-12-20 07:00AM  
Mar-05-20 07:00AM  
Mar-04-20 07:00AM  
Mar-02-20 10:33AM  
Feb-20-20 07:00AM  
Feb-19-20 07:00AM  
Jan-28-20 06:32PM  
Jan-23-20 09:34AM  
Jan-22-20 07:00AM  
Jan-17-20 08:45AM  
Jan-13-20 06:00AM  
Jan-09-20 02:50PM  
Jan-03-20 10:44AM  
Jan-02-20 07:57AM  
Dec-31-19 09:26AM  
Dec-30-19 06:15AM  
Dec-27-19 02:19PM  
Dec-24-19 12:15PM  
Dec-23-19 04:19PM  
Dec-22-19 05:05AM  
Dec-20-19 08:12AM  
Dec-19-19 12:50PM  
Dec-18-19 04:01PM  
Dec-17-19 07:56AM  
Dec-16-19 08:43AM  
Dec-11-19 11:04PM  
Dec-06-19 08:00AM  
Dec-04-19 10:02AM  
Dec-03-19 08:56AM  
Nov-21-19 07:00AM  
Nov-20-19 05:28PM  
Nov-07-19 07:00AM  
Oct-29-19 07:00AM  
Oct-28-19 01:23PM  
Oct-21-19 07:00AM  
Oct-16-19 07:00AM  
Oct-03-19 08:41AM  
Oct-02-19 07:00AM  
Oct-01-19 08:54AM  
Sep-18-19 02:08PM  
Sep-04-19 01:25PM  
Sep-03-19 07:00AM  
Aug-31-19 01:19AM  
Aug-29-19 08:58AM  
Aug-20-19 07:00AM  
Aug-09-19 11:52AM  
Aug-08-19 07:00AM  
Jul-30-19 07:00AM  
Jul-29-19 07:00AM  
Jul-16-19 07:46PM  
Jul-12-19 08:50AM  
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorJun 29Buy78.5065051,025403,698Jun 30 08:20 AM
Pizzie NickChief Financial OfficerJun 29Buy76.6477759,54941,217Jun 30 08:19 AM
JEFFS ROGERDirectorJan 10Option Exercise10.4660,186629,756116,806Jan 14 04:08 PM
Pizzie NickChief Financial OfficerSep 26Buy24.802,18054,06440,440Sep 30 07:16 AM